MolNFT v1 · #50514 · protein
HIV-1 pr resistant mutant + lpv
2RKG · Protease retropepsin: “HIV-1 pr resistant mutant + lpv”. X-ray diffraction, 1 ligand (AB1), 1 pocket (best druggability 0.71). MolNFT v1 #50514 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 2RKG
- Type
- protein
- Length
- 200 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Protease retropepsin
- EC
- 3.4.23.16
- UniProt
- A0F7J4
- Ligands
- AB1
- Pockets
- 1 · best druggability 0.71
Structure
x-ray diffraction · 1 distinct chain · 7% helix, 53% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, B | Protease retropepsin (EC 3.4.23.16) | protein | 100 | 7% helix, 53% strand | A0F7J4 |
Ligands and binding sites
- AB1 · N-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide · ligand · chains A, B
- GOL · Glycerol · additive · 2 copies · chains A, B
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 423 | 0.71 | 0.81 | 38 | AB1 |
Interfaces
1 interface between chains.
- A–B · 1808 Ų buried · 39 hydrogen bonds · protein-protein
Compared structures
- 2RKG · HIV-1 PR resistant mutant + LPV · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt A0F7J4
- Elsewhere: RCSB PDB 2RKG · PDBe 2RKG · UniProt A0F7J4
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.